Robert E Landry Regeneron Pharmaceuticals, Inc. (REGN) insider trading activity

Robert E Landry is EVP Finance CFO of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 23,693 shares of REGN, which is worth approximately $19.5 Million. The most recent transaction as insider was on Dec 08, 2021, when has been sold 3,971 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 23.7K

0% 3M change

25.26% 12M change

Total Value Held $19.5 Million

Robert E Landry Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 08 2021	BUY Grant, award, or other acquisition	-	3,971 Added 11.7%	29,957 Common Stock
Nov 17 2021	SELL Open market or private sale	$439,299 $645.08 p/Share	681 Reduced 2.55%	25,986 Common Stock
Nov 16 2021	SELL Payment of exercise price or tax liability	$2,000,896 $651.97 p/Share	3,069 Reduced 10.32%	26,667 Common Stock
Nov 16 2021	BUY Exercise of conversion of derivative security	$1,498,725 $399.66 p/Share	3,750 Added 11.2%	29,736 Common Stock
Aug 31 2021	SELL Payment of exercise price or tax liability	$619,003 $675.03 p/Share	917 Reduced 3.41%	25,986 Common Stock
Aug 31 2021	BUY Exercise of conversion of derivative security	$555,670 $555.67 p/Share	1,000 Added 3.58%	26,903 Common Stock
Aug 10 2021	SELL Open market or private sale	$330,362 $615.2 p/Share	537 Reduced 2.03%	25,903 Common Stock
Aug 09 2021	SELL Open market or private sale	$224,530 $616.84 p/Share	364 Reduced 1.39%	25,903 Common Stock
Aug 09 2021	SELL Payment of exercise price or tax liability	$1,521,346 $617.68 p/Share	2,463 Reduced 8.52%	26,440 Common Stock
Aug 09 2021	BUY Exercise of conversion of derivative security	$1,145,760 $381.92 p/Share	3,000 Added 9.4%	28,903 Common Stock
Aug 06 2021	SELL Payment of exercise price or tax liability	$993,886 $607.51 p/Share	1,636 Reduced 5.86%	26,267 Common Stock
Aug 06 2021	BUY Exercise of conversion of derivative security	$763,840 $381.92 p/Share	2,000 Added 6.69%	27,903 Common Stock
Dec 09 2020	BUY Grant, award, or other acquisition	-	1,930 Added 6.93%	25,903 Common Stock

REL

Robert E Landry

EVP Finance CFO

Tarrytown, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Value

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN

Account